摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2,4-bis(benzyloxy)-5-isobutylphenyl)-4-iodoisoxazole-3-carboxylic acid ethylamide | 747414-52-4

中文名称
——
中文别名
——
英文名称
5-(2,4-bis(benzyloxy)-5-isobutylphenyl)-4-iodoisoxazole-3-carboxylic acid ethylamide
英文别名
5-(2,4-dibenzyloxy-5-isobutylphenyl)-N-ethyl-4-iodoisoxazole-3-carboxamide;5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide;N-ethyl-4-iodo-5-[5-(2-methylpropyl)-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxamide
5-(2,4-bis(benzyloxy)-5-isobutylphenyl)-4-iodoisoxazole-3-carboxylic acid ethylamide化学式
CAS
747414-52-4
化学式
C30H31IN2O4
mdl
——
分子量
610.492
InChiKey
SOSICOHQADBISY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.2
  • 重原子数:
    37
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    73.6
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(2,4-bis(benzyloxy)-5-isobutylphenyl)-4-iodoisoxazole-3-carboxylic acid ethylamide4-甲酰基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下, 以 DMF (N,N-dimethyl-formamide) 、 为溶剂, 反应 2.17h, 生成 5-(2,4-bis(benzyloxy)-5-isobutylphenyl)-4-(4-formylphenyl)isoxazole-3-carboxylic acid ethylamide
    参考文献:
    名称:
    [EN] ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
    [FR] COMPOSES D'ISOXAZOLE UTILES COMME INHIBITEURS DES PROTEINES DE CHOC THERMIQUE
    摘要:
    式(A)或(B)的异唑唑烷是HSP90活性的抑制剂,可用于治疗癌症等疾病:其中R1是式(IA)的一个基团:-Ar1-(Alk1)p-(Z)r-(Alk2)S-Q,其中在任何兼容的组合中,Ar1是可选择地取代的芳基或杂环基团,Alk1和Alk2是可选择地取代的二价Cl-C6烷基或C2-C6烯基基团,p、r和s独立地为0或1,Z是-0-,-S-,-(C=O)-,-(C=S)-,-SO2-,-C(=O)O-,-C(=O)NRA-,-C(=S)NRA-,-SO2NRA-,-NRAC(=O)-,-NRASO2-或-NRA-,其中RA是氢或Cl-C6烷基,Q是氢或一个可选择地取代的脂环或杂环基团;R2是(i)上述式(IA)的一个基团或(ii)一个羧酰胺基团;或(iii)一个非芳香的脂环或杂环环,其中一个环碳原子可选择地取代,和/或一个环氮原子可选择地被一个式-(Alk1)p-(Z)r-(Alk2)s-Q的基团取代,其中Q、Alk1、Alk2、Z、p、r和s如上所述与式(IA)相关的基团定义;R3是氢,可选择地取代的环烷基、环烯烃基、C1-C6烷基、C1-C6烯基或C1-C6炔基;或一个羧基、羧酰胺基或羧酸酯基团。
    公开号:
    WO2004072051A1
  • 作为产物:
    参考文献:
    名称:
    EP3248968
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Isoxazole compounds as inhibitors of heat shock proteins
    申请人:Drysdale James Martin
    公开号:US20060241106A1
    公开(公告)日:2006-10-26
    Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R 1 , is a group of formula (IA): —Ar 1 -(Alk 1 )p-(Z) r -(Alk 2 ) s -Q, wherein in any compatible combination Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 6 alkylene or C 2 -C 6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO 2 —, —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, —NR A SO 2 — or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk 1 )p-(Z) r -(Alk 2 ) s -Q wherein Q, Alk 1 , Alk 2 , Z, p, r and s are as defined above in relation to group (IA); and R 3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
    式(A)或(B)的异噁唑是HSP90活性的抑制剂,可用于治疗癌症等疾病:(A)、(B)其中R1是以下式子的基团:-Ar1-(Alk1)p-(Z)r-(Alk2)s-Q,其中在任何兼容的组合中,Ar1是可选取代的芳基或杂环基团,Alk1和Alk2是可选取代的二价C1-C6烷基或C2-C6烯基基团,p、r和s是独立的0或1,Z是-0-、-S-、-(C═O)-、-(C═S)-、-SO2-、-C(═O)O-、-C(═O)NRA-、-C(═S)NRA-、-SO2NRA-、-NRAC(═O)-、-NRASO2-或-NRA-,其中RA是氢或C1-C6烷基,Q是氢或可选取代的碳环或杂环基团;R2是(i)上述式(Ia)的基团,或(ii)羧酰胺基团,或(iii)非芳香碳环或杂环环,其中一个环碳原子可选取代,和/或一个环氮原子可选取代为以下式子的基团:-(Alk1)p-(Z)r-(Alk2)s-Q,其中Q、Alk1、Alk2、Z、p、r和s如上所述;R3是氢、可选取代的环烷基、环烯基、C1-C6烷基、C1-C6烯基或C1-C6炔基;或羧基、羧酰胺基或羧酸酯基团。
  • Isoxazole Compounds As Inhibitors Of Heat Shock Proteins
    申请人:Drysdale Martin James
    公开号:US20120252797A1
    公开(公告)日:2012-10-04
    Isoxazoles of formula (A) or (B) wherein R 1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.
    化合物的式子为(A)或(B),其中R1为式子(IB)所代表的基团。这些异噁唑是HSP90活性的抑制剂,可用于治疗癌症等疾病。
  • Isozazole Compounds As Inhibitors Of Heat Shock Proteins
    申请人:Drysdale Martin James
    公开号:US20100179138A1
    公开(公告)日:2010-07-15
    Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R 1 , is a group of formula (IA): —Ar 1 -(Alk 1 ) p -(Z) r -(Alk 2 ) s -Q, wherein in any compatible combination Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 6 alkylene or C 2 -C 6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, —NR A SO 2 —or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk 1 ) p -(Z) r -(Alk 2 ) s -Q wherein Q, Alk 1 , Alk 2 , Z, p, r and s are as defined above in relation to group (IA); and R 3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
    式(A)或(B)的异噁唑是HSP90活性的抑制剂,可用于治疗癌症,例如:其中R1是以下式(IA)的基团:—Ar1-(Alk1)p-(Z)r-(Alk2)s-Q,其中在任何兼容的组合中,Ar1是可选取代的芳基或杂环芳基基团,Alk1和Alk2是可选取代的二价C1-C6烷基或C2-C6烯基基团,p,r和s独立地为0或1,Z为-0-,—S—,—(C═O)—,—(C═S)—,—SO.sub.2-,—C(═O)O—,—C(═O)NRA—,—C(═S)NRA—,—SO2NRA—,—NRAC(═O)—,—NRASO2—或—NRA—,其中RA为氢或C1-C6烷基,并且Q为氢或可选取代的碳环或杂环基团;R2为(i)上述式(IA)的基团或(ii)一个羧酰胺基团;或(iii)一个非芳香碳环或杂环环,其中一个环碳原子可选取代,和/或一个环氮原子可选取代为以下式的基团-(Alk1)p-(Z)r-(Alk2)s-Q,其中Q,Alk1,Alk2,Z,p,r和s如上所述定义于基团(IA);和R3为氢,可选取代的环烷基,环烯基,C1-C6烷基,C1-C6烯基或C1-C6炔基;或羧基,羧酰胺基或羧酸酯基。
  • RESORCINOL DERIVATIVE AS HSP90 INHIBITOR
    申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    公开号:EP3248968A1
    公开(公告)日:2017-11-29
    The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.
    本发明涉及一种由式(I)代表的间苯二酚生物作为 HSP90 抑制剂的化合物或其药用盐。本发明中的化合物具有抑制热休克蛋白 HSP90 的活性。因此,本发明中的化合物可用于治疗增殖性疾病,如癌症和神经退行性疾病。本发明进一步提供了本发明化合物和包含本发明化合物的药物组合物的制备方法、治疗疾病的方法和包含本发明化合物的药物组合物。
  • Resorcinol derivative as HSP90 inhibitor
    申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    公开号:US10035792B2
    公开(公告)日:2018-07-31
    The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.
    本发明涉及一种由式(I)代表的间苯二酚生物作为 HSP90 抑制剂的化合物或其药用盐。本发明中的化合物具有抑制热休克蛋白 HSP90 的活性。因此,本发明中的化合物可用于治疗增殖性疾病,如癌症和神经退行性疾病。本发明进一步提供了本发明化合物和包含本发明化合物的药物组合物的制备方法、治疗疾病的方法和包含本发明化合物的药物组合物。
查看更多